These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 23924450

  • 1. Evaluation of efficacy and safety of sunitinib regimen in 22 patients with metastatic renal cell carcinoma: at least 12-month follow-up.
    Zhang CJ, Zhao PJ, Li XS, Zhao J, Huang LH, Song Y, Gong K, Shen C, Yu W, Song G, Zhao Z, Zhang Z, Zhang Q, He ZS, Jin J, Zhou LQ.
    Chin Med J (Engl); 2013; 126(15):2826-9. PubMed ID: 23924450
    [Abstract] [Full Text] [Related]

  • 2. Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma.
    Barrios CH, Hernandez-Barajas D, Brown MP, Lee SH, Fein L, Liu JH, Hariharan S, Martell BA, Yuan J, Bello A, Wang Z, Mundayat R, Rha SY.
    Cancer; 2012 Mar 01; 118(5):1252-9. PubMed ID: 21898376
    [Abstract] [Full Text] [Related]

  • 3. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma.
    Escudier B, Roigas J, Gillessen S, Harmenberg U, Srinivas S, Mulder SF, Fountzilas G, Peschel C, Flodgren P, Maneval EC, Chen I, Vogelzang NJ.
    J Clin Oncol; 2009 Sep 01; 27(25):4068-75. PubMed ID: 19652072
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Experience with sunitinib treatment for metastatic renal cell carcinoma in a large cohort of Israeli patients: outcome and associated factors.
    Livne-Segev D, Gottfried M, Maimon N, Peer A, Neumann A, Hayat H, Kovel S, Sella A, Mermershtain W, Rouvinov K, Boursi B, Weitzen R, Berger R, Keizman D.
    Isr Med Assoc J; 2014 Jun 01; 16(6):347-51. PubMed ID: 25058995
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and Safety of an Attenuated-Dose Sunitinib Regimen in Metastatic Renal Cell Carcinoma: Results From a Prospective Registry in Singapore.
    Tan HS, Li H, Hong YW, Toh CK, Wong A, Lopes G, Tay MH, Chan A, Yao X, Tang T, Ng QS, Kanesvaran R, Chau NM, Tan MH.
    Clin Genitourin Cancer; 2015 Aug 01; 13(4):e285-e295. PubMed ID: 25541325
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Alternative dosing schedules for sunitinib as a treatment of patients with metastatic renal cell carcinoma.
    Guida FM, Santoni M, Conti A, Burattini L, Savini A, Zeppola T, Caricato M, Cascinu S, Tonini G, Santini D.
    Crit Rev Oncol Hematol; 2014 Dec 01; 92(3):208-17. PubMed ID: 25151214
    [Abstract] [Full Text] [Related]

  • 10. Sunitinib in patients with metastatic renal cell carcinoma.
    Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD.
    JAMA; 2006 Jun 07; 295(21):2516-24. PubMed ID: 16757724
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and tolerability of a low-dose, 2-week administration of sunitinib followed by a week rest (2/1 schedule) for metastatic renal cell carcinoma: a single center experience of six cases.
    Makino K, Yoda K, Tomoishi J, Kume H.
    BMC Res Notes; 2014 Dec 04; 7():872. PubMed ID: 25471941
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Sunitinib 4/2 Versus 2/1 Schedule for Patients With Metastatic Renal Cell Carcinoma: Tertiary Care Hospital Experience.
    Ezz El Din M.
    Clin Genitourin Cancer; 2017 Jun 04; 15(3):e455-e462. PubMed ID: 28392154
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of sunitinib in the treatment of metastatic renal cell carcinoma.
    Li XS, Wu X, Zhao PJ, Huang LH, Song Y, Gong K, Shen C, Yu W, Song G, Zhao Z, Zhang Z, Zhang Q, Wang G, He ZS, Zhou LQ, Jin J.
    Chin Med J (Engl); 2011 Sep 04; 124(18):2920-4. PubMed ID: 22040503
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma.
    Rautiola J, Donskov F, Peltola K, Joensuu H, Bono P.
    BJU Int; 2016 Jan 04; 117(1):110-7. PubMed ID: 25252180
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Real-life patterns of use, safety and effectiveness of sunitinib in first-line therapy of metastatic renal cell carcinoma: the SANTORIN cohort study.
    Noize P, Grelaud A, Bay JO, Chevreau C, Gross-Goupil M, Culine S, Ferrière JM, Moulin F, Robinson P, Balestra A, Lamarque S, Bernard MA, Lassalle R, Rouyer M, Droz-Perroteau C, Moore N, Fourrier-Réglat A, Ravaud A.
    Pharmacoepidemiol Drug Saf; 2017 Dec 04; 26(12):1561-1569. PubMed ID: 28573786
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.